Search

Your search keyword '"Ostwald, Dennis A"' showing total 48 results
Start Over Author "Ostwald, Dennis A"
48 results on '"Ostwald, Dennis A"'

1. Radiotherapy and theranostics: a Lancet Oncology Commission

Author

Abdel-Wahab, May, Giammarile, Francesco, Carrara, Mauro, Paez, Diana, Hricak, Hedvig, Ayati, Nayyereh, Li, Jing Jing, Mueller, Malina, Aggarwal, Ajay, Al-Ibraheem, Akram, Alkhatib, Sondos, Atun, Rifat, Bello, Abubakar, Berger, Daniel, Delgado Bolton, Roberto C, Buatti, John M, Burt, Graeme, Bjelac, Olivera Ciraj, Cordero-Mendez, Lisbeth, Dosanjh, Manjit, Eichler, Thomas, Fidarova, Elena, Gondhowiardjo, Soehartati, Gospodarowicz, Mary, Grover, Surbhi, Hande, Varsha, Harsdorf-Enderndorf, Ekaterina, Herrmann, Ken, Hofman, Michael S, Holmberg, Ola, Jaffray, David, Knoll, Peter, Kunikowska, Jolanta, Lewis, Jason S, Lievens, Yolande, Mikhail-Lette, Miriam, Ostwald, Dennis, Palta, Jatinder R, Peristeris, Platon, Rosa, Arthur A, Salem, Soha Ahmed, dos Santos, Marcos A, Sathekge, Mike M, Shrivastava, Shyam Kishore, Titovich, Egor, Urbain, Jean-Luc, Vanderpuye, Verna, Wahl, Richard L, Yu, Jennifer S, Zaghloul, Mohamed Saad, Zhu, Hongcheng, and Scott, Andrew M

Published
2024
Full Text
View/download PDF

17. 6 Fazit

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

18. Literaturverzeichnis

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

20. 2 Methodische Vorüberlegungen

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

23. 1 Ausgangslage und Aufbau des Gutachtens

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

24. Titelei/Inhaltsverzeichnis

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

25. Management Summary

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

26. A 2 Methodischer Anhang

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

28. 4 Der Arbeitsmarkt in der GGR

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

29. A 1 Tabellarischer Anhang

Author

Heeger, Dirk, primary, Henke, Klaus-Dirk, additional, Hesse, Sebastian, additional, Kim, Zun-Gon, additional, Knippel, Julian, additional, Mosetter, Heiko, additional, Ostwald, Dennis A., additional, Perlitz, Wolf-Dieter, additional, Richter, Tobias, additional, and Troppens, Sabine, additional

Published
2014
Full Text
View/download PDF

30. sj-pdf-1-cep-10.1177_0333102420944842 - Supplemental material for The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany

Author

Seddik, Ahmed H, Branner, Jennifer C, Ostwald, Dennis A, Schramm, Sara H, Bierbaum, Martin, and Katsarava, Zaza

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-1-cep-10.1177_0333102420944842 for The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany by Ahmed H Seddik, Jennifer C Branner, Dennis A Ostwald, Sara H Schramm, Martin Bierbaum and Zaza Katsarava in Cephalalgia

Published
2020
Full Text
View/download PDF

34. Health economy reporting - A useful tool to support sustainable investment in health and development

Author

Werling, Esther, Hamelmann, Christoph, Henke, Klaus-Dirk, Legler, Benno, Claus, Mirko, and Ostwald, Dennis A.

Subjects
DDC::600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, economic footprint, DDC::300 Sozialwissenschaften::330 Wirtschaft::330 Wirtschaft, national accounts, Gesundheitswirtschaft, Ökonomischer Fußabdruck, health economy, Gesundheitswesen, health policy, Gesundheitspolitik, health care, health care economics and organizations
Abstract

Governments all over the world need to target investments in health to generate jobs and promote inclusive and sustainable economic growth as they implement the 2030 Agenda for Sustainable Development. This report reviews a well-established methodology of health economy reporting that quantifies and analyses the health sector’s economic impact on growth and employment based on national accounts. The report concludes that the methodology enables evidence-based health policy to steer and guide investments for health, employment and inclusive and sustainable growth. Value- and evidence-based public health investment provides effective and efficient, inclusive and innovative solutions that can drive social, economic and environmental sustainability. Investing for health and well-being is a driver and enabler of sustainable development and empowers people to achieve the highest attainable standard of health for all., Weltweit stehen Regierungen und politische Entscheidungsträger vor der Herausforderung, bei der Implementierung der Agenda 2030 für nachhaltige Entwicklung auch Investitionen in Gesundheit zu berücksichtigen, um auf diese Weise Arbeitsplätze zu schaffen und ein inklusives und nachhaltiges Wirtschaftswachstum zu bewirken. Der vorliegende Bericht stellt eine mit der Gesundheitswirtschaftlichen Gesamtrechnung (GGR) anerkannte Methodik zur Bemessung der Gesundheitswirtschaft und deren Bedeutung für wirtschaftliches Wachstum und Beschäftigung auf Basis amtlicher Daten der Volkswirtschaftlichen Gesamtrechnungen (VGR) vor. Dabei wird festgestellt, dass die in Deutschland angewendete Methodik der GGR unterstützend wirkt, eine faktenbasierte Gesundheitswirtschaftspolitik zu etablieren und zielgerichtete Investitionen in Gesundheit, Beschäftigung und nachhaltiges wirtschaftliches Wachstum zu lenken. Evidenzbasierte Investitionen im Gesundheitswesen bieten effektive und effiziente, integrative und innovative Lösungen, die die soziale, wirtschaftliche und ökologische Nachhaltigkeit fördern können. Investitionen in Gesundheit und Wohlbefinden stellen daher einen wichtigen Einflussfaktor für eine nachhaltige Entwicklung dar und befähigen eine Gesellschaft darin, den höchstmöglichen Gesundheitsstandard für alle zu erreichen.

Published
2018
Full Text
View/download PDF

37. Der Social Impact von Secukinumab - Eine Studie zu langfristigen volkswirtschaftlichen Effekten der Anwendung eines Biologikums in der Behandlung der Psoriasis Arthritis

Author

Ostwald, Dennis, Müller, Malina, and Himmler, Sebastian

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Psoriasis Arthritis (PsA) geht mit erheblichen Einschränkungen des beruflichen und privaten Alltags einher. Durch den Markteintritt verschiedener Biologika wurden den Patienten innerhalb der letzten Jahre effektive Therapieoptionen verfügbar gemacht, die zur Reduzierung der Krankheitslast[zum vollständigen Text gelangen Sie über die oben angegebene URL], 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2017

38. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany.

Author

Himmler, Sebastian, Mueller, Malina, Sherif, Bintu, and Ostwald, Dennis

Abstract

Objectives: Psoriatic arthritis (PsA) is associated with serious productivity impairment. Secukinumab, a fully human IL-17A inhibitor, provides sustained relief from PsA symptoms. This study estimates the societal economic benefits of using secukinumab instead of conventional disease-modifying anti-rheumatic drugs (DMARDs) for treating patients with active PsA in Germany from 2016 to 2030.Methods: A Markov and a population model simulated the functional impairment of German PsA patients. The relationship between functional impairment and work productivity was used to determine the productivity difference in the populations treated with secukinumab and csDMARDs. The corresponding gains in productive time were allocated to paid and unpaid activities and valued according to gross value added (GVA). Since increased productivity has the potential to stimulate greater macroeconomic effects, indirect and induced GVA effects were calculated as well.Results: The use of secukinumab reduces the productivity impairment in the target population on average by 13 percentage points. This difference could generate 32 million active and productive hours until the year 2030, which translates to GVA equivalents of €1.3 billion. Including indirect and induced effects yield an economic estimate of €2.7 billion GVA equivalent.Conclusions: The improvements in PsA-related functional impairment could lead to sizable productivity effects within the economy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

41. The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab

Author

Himmler, Sebastian, Branner, Jennifer C, and Ostwald, Dennis A

Abstract

Aim:This study estimates the societal benefits of using biologics like secukinumab (SEC) instead of nonsteroidal anti-inflammatory drugs for treating patients with ankylosing spondylitis in Germany. Materials & methods:A Markov and a population model were used to predict the functional impairment of German ankylosing spondylitis patients using SEC or nonsteroidal anti-inflammatory drugs. This was translated into avoided productivity losses, which were valued according to gross value added. Results:The productivity impairment of SEC users was predicted to decrease by 20 percentage points, corresponding to 12.8 and 32.7 million hours in paid and unpaid work and a monetary value of €1.6 billion from 2016 to 2030. Accounting for economic spillover effects increases the societal value to € 3.3 billion. Conclusion:The improvements in functional impairment due to biologics could lead to sizable productivity effects.

Published
2020
Full Text
View/download PDF

42. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.

Author

Himmler, Sebastian, Müller, Malina, Ostwald, Dennis, Seddik, Ahmed, Basic, Edin, and Hradetzky, Eva

Abstract

Background: Patients with non-valvular atrial fibrillation (NVAF) have a five times higher stroke risk. For more than 50 years, vitamin K antagonists (VKAs) have been the primary medication for stroke prevention. Apixaban, a non-vitamin K oral anticoagulant (NOAC), has demonstrated better efficacy and safety characteristics than the VKA warfarin in the ARISTOTLE trial. This study aims to quantify the potential societal effects of using apixaban instead of VKA in the German NVAF population from 2017 to 2030.Methods: Using an existing Markov model and a dynamic population approach, we modelled the health benefits of apixaban in patients with NVAF compared to VKA therapy in the German population from 2017 to 2030.Results: The results represent the extrapolated direct long-term health benefits of apixaban over VKA therapy for the German NVAF population. From 2017 until 2030, the use of apixaban instead of a VKA could avoid 52,185 major clinical events. This includes 15,383 non-fatal strokes or SEs, 22,483 non-fatal major bleeds, and 14,319 all-cause deaths, which correspond to 109,887 life years gained.Conclusion: This study demonstrated that using apixaban instead of VKA for stroke prevention can lead to considerable reduction in cardiovascular events. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. [Strength and weaknesses of the German digital health economy].

Author

Leppert F, Gerlach J, Ostwald DA, and Greiner W

Subjects
Commerce, Germany, Delivery of Health Care economics, Economics, Medical, Telemedicine economics
Abstract

There are high expectations from digitalization of health care, ehealth and telemedicine. Nevertheless, the diffusion of these services falls short of expectations. This study analyses the strength and weaknesses of the German digital health economy. Thereby, we specially focus on small and medium-sized enterprises (SME). The study is based on a literature review, interviews of experts and a workshop. The digital health economy is influenced by a heterogeneous environment with both promotive and obstructive factors. One of the largest weaknesses results from a lack of business models. There is a lack of possibilities of reimbursement by the Statutory Health Insurance (SHI). In addition, private users only have a small willingness to pay for digital services. The large number of regulations makes the implementation even harder, especially for SMEs. Thus, the current environment hampers fast diffusion of digital services in the German health care market., Competing Interests: Die Autoren geben an, dass kein Interessenskonflikt besteht., (© Georg Thieme Verlag KG Stuttgart · New York.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results